本文選題：恩替卡韋 + 苦參素　； 參考：《中華醫(yī)院感染學雜志》2017年07期

【摘要】：目的探討恩替卡韋聯(lián)合苦參素治療慢性乙型肝炎的有效性研究,為慢性乙型肝炎的治療提供參考。方法選取2014年6月-2015年6月醫(yī)院收治的100例慢性乙型肝炎患者,分為觀察組與對照組,各50例;對照組僅服用恩替卡韋治療,觀察組加用苦參素口服,比較兩組患者臨床指標。結(jié)果兩組治療后膽紅素(TBil)、門冬氨酸氨基轉(zhuǎn)移酶(AST)、丙氨酸氨基轉(zhuǎn)移酶(ALT)、HBV-DNA水平均與治療前比較下降,觀察組較對照組下降幅度明顯,差異有統(tǒng)計學意義(P0.05);兩組HA、LN、IV-C、PCⅢ水平治療后均與治療前比較下降,觀察組較對照組下降幅度明顯(P0.05)。結(jié)論恩替卡韋聯(lián)合苦參素治療慢性乙型肝炎能明顯提高病毒血清標志物轉(zhuǎn)陰率及改善肝纖維化狀態(tài),提高臨床治療效果。
[Abstract]:Objective to investigate the efficacy of entecavir combined with matrine in the treatment of chronic hepatitis B (CHB). Methods from June 2014 to June 2015, 100 patients with chronic hepatitis B were divided into the observation group and the control group, 50 cases in each group, the control group was treated only with entecavir, the observation group was treated with matrine orally, and the clinical indexes of the two groups were compared. Results after treatment, the levels of bilirubin T bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (alanine aminotransferase) in the two groups were all decreased compared with those before treatment, and the levels of HBV-DNA in the observation group were significantly lower than those in the control group. The difference was statistically significant (P 0.05), the level of Hal LNV IV-CU PC 鈪，

本文編號：2031686